摘要
Anti-tumor immunotherapy is an important form of adjuvant cancer treatment [1, 2]. While chemotherapy encounters the obstacles of drug toxicity and resistance, immunotherapy usually has limited adverse effects, good patient tolerance, and the potential to significantly improve the prognosis [1-4]. Some clinical trials of im- munotherapy generated promising results in treating malignancies such as malignant melanoma, glioblastoma multiforme, or renal cell carcinoma, which tend to re- spond poorly to chemotherapies [3-5]. Dendritic cells (DC) play a crucial role in generating specific immune reaction to antigens, which generally need to be ingested, processed and presented by DC, before triggering B cell- or T cell- mediated responses. This core immune mechanism has been utilized in designing DC-based anticancer immunotherapy, whereby a patient's DC are expanded with in vitro culture,
